These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 17682340)

  • 21. Urokinase plasminogen activator (uPA) and its receptor (uPAR) in gestational tissues; Measurements and clinical implications.
    Uszyński M; Perlik M; Uszyński W; Zekanowska E
    Eur J Obstet Gynecol Reprod Biol; 2004 May; 114(1):54-8. PubMed ID: 15099871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urokinase-type plasminogen activator system and breast cancer (Review).
    Han B; Nakamura M; Mori I; Nakamura Y; Kakudo K
    Oncol Rep; 2005 Jul; 14(1):105-12. PubMed ID: 15944776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer.
    de Bock CE; Wang Y
    Med Res Rev; 2004 Jan; 24(1):13-39. PubMed ID: 14595671
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vitronectin binding to urokinase receptor in human breast cancer.
    Carriero MV; Del Vecchio S; Franco P; Potena MI; Chiaradonna F; Botti G; Stoppelli MP; Salvatore M
    Clin Cancer Res; 1997 Aug; 3(8):1299-308. PubMed ID: 9815812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.
    Ploug M; Ostergaard S; Hansen LB; Holm A; Danø K
    Biochemistry; 1998 Mar; 37(11):3612-22. PubMed ID: 9521680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1-infected patients.
    Ostrowski SR; Piironen T; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
    Scand J Immunol; 2005 Apr; 61(4):347-56. PubMed ID: 15853918
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metalloproteases cleave the urokinase-type plasminogen activator receptor in the D1-D2 linker region and expose epitopes not present in the intact soluble receptor.
    Andolfo A; English WR; Resnati M; Murphy G; Blasi F; Sidenius N
    Thromb Haemost; 2002 Aug; 88(2):298-306. PubMed ID: 12195704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancer.
    Almasi CE; Høyer-Hansen G; Christensen IJ; Pappot H
    APMIS; 2009 Oct; 117(10):755-61. PubMed ID: 19775344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
    Duffy MJ; Duggan C
    Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.
    Pedersen N; Schmitt M; Rønne E; Nicoletti MI; Høyer-Hansen G; Conese M; Giavazzi R; Dano K; Kuhn W; Jänicke F
    J Clin Invest; 1993 Nov; 92(5):2160-7. PubMed ID: 8227331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential binding of urokinase and peptide antagonists to the urokinase receptor: evidence from characterization of the receptor in four primate species.
    Engelholm LH; Behrendt N
    Biol Chem; 2001 Mar; 382(3):435-42. PubMed ID: 11347891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evolving role of uPA/uPAR system in human cancers.
    Dass K; Ahmad A; Azmi AS; Sarkar SH; Sarkar FH
    Cancer Treat Rev; 2008 Apr; 34(2):122-36. PubMed ID: 18162327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
    Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
    Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR).
    Beaufort N; Debela M; Creutzburg S; Kellermann J; Bode W; Schmitt M; Pidard D; Magdolen V
    Biol Chem; 2006 Feb; 387(2):217-22. PubMed ID: 16497155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential proteome expression associated with urokinase plasminogen activator receptor (uPAR) suppression in malignant epithelial cancer.
    Saldanha RG; Xu N; Molloy MP; Veal DA; Baker MS
    J Proteome Res; 2008 Nov; 7(11):4792-806. PubMed ID: 18808175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma.
    Bhuvarahamurthy V; Schroeder J; Kristiansen G; Roigas J; Denkert C; Johannsen M; Lein M; Loening SA; Schnorr D; Jung K; Staack A
    Oncol Rep; 2005 Sep; 14(3):777-82. PubMed ID: 16077991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle.
    Nordengren J; Pilka R; Noskova V; Ehinger A; Domanski H; Andersson C; Høyer-Hansen G; Hansson SR; Casslén B
    Mol Hum Reprod; 2004 Sep; 10(9):655-63. PubMed ID: 15243126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Association of uPA and uPAR expression with invasive behaviors of urinary transitional cell carcinoma].
    Li YJ; Zheng BZ; Zhou ZL
    Ai Zheng; 2004 Jun; 23(6):704-6. PubMed ID: 15191676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis.
    He Y; Liu XD; Chen ZY; Zhu J; Xiong Y; Li K; Dong JH; Li X
    Clin Cancer Res; 2007 Jun; 13(11):3115-24. PubMed ID: 17545513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients.
    Lomholt AF; Christensen IJ; Høyer-Hansen G; Nielsen HJ
    Acta Oncol; 2010 Aug; 49(6):805-11. PubMed ID: 20524776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.